Allogene Therapeutics Inc (NAS:ALLO)
$ 2.99 -0.01 (-0.33%) Market Cap: 625.25 Mil Enterprise Value: 269.70 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 34/100

Allogene Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 02:30PM GMT
Release Date Price: $43.05 (+1.16%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. We're pleased to have Allogene with us here this morning. And with us, we have David Chang, President and CEO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

David, you recently presented initial data from the Phase I ALLO-501 study, your allogeneic CAR T at ASCO this year. Could you start by briefly recapping these findings and help put into context for us, how we should think about these results compared to the early autologous CAR T data?

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

Yes, Salveen, it's a pleasure to be invited to this conference. And too bad that we have to hold this as a virtual conference. I mean, I always love to go down to the Goldman Sachs conference at a wonderful time in June in Southern California, but such is the life nowadays. So we have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot